Full-Time

Business Capability Lead

Supplier Collaboration

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Sant Cugat del Vallès, Barcelona, Spain

In Person

On-site role based in Sant Cugat del Vallès, Spain.

Category
Business & Strategy (1)
Required Skills
SAP Products

Get referred to Roche

Find people who can refer or advise you

Requirements
  • A University degree with a business or life sciences focus is required.
  • Deep expert knowledge of procurement systems and enterprise architectures (specifically SAP S/4HANA, GEP Smart/GEP Nexxe).
  • Extensive experience in the design, management, and continuous improvement of complex business processes, with distinct experience operating within the Demand-to-Pay landscape.
  • Advanced knowledge in AI application and a strong affinity to explore AI-driven solutions broadly, particularly regarding the digital transformation of operations (Digital 2.0 / Industry 4.0).
  • Proven track record of guiding stakeholder groups, managing escalations, navigating communication lines, and leading cross-functional project teams without direct headcount authority.
  • A self-organized, motivated professional with a solution-oriented "Can-Do" attitude and an end-to-end business perspective. You possess excellent negotiation and conflict resolution skills, acting as a customer-oriented partner who champions an open speak-up and error culture.
  • Business-level fluency in English is required.
  • German language skills are a strong asset.
Responsibilities
  • Develop and deploy the DOP roadmap for iCollab and other adjoining solutions, in alignment with functional partners like DIA Global Supply Chain and RSS Demand to Pay.
  • Proactively identifying opportunities for process automation and digitalization in close collaboration with Delivery, Category, Digital & Process Management, and RSS Demand to Pay.
  • Acting as a subject matter expert to analyze, elaborate options, and design solutions that resolve process, system, performance indicator, or data concerns, while supporting data and rule definitions.
  • Serving as a responsible delegate on major corporate initiatives (such as the ASPIRE program; our overarching process and digital transformation) to support global template adoption and evaluate localized change impacts.
  • Leading continuous improvement initiatives, managing global requirement alignment, and partnering with fellow BCLs and Business Capability Owners to optimize end-to-end cross-functional performance.
  • Leading the Business Capability Community of SMEs and representing DOP in communities and Agile Release Trains.
  • Governing the development, structural maintenance, and delivery of global system process documentation and training materials.
  • Resolving matrix conflicts regarding competing project priorities or process expectations, while delivering high-frequency monthly or quarterly KPI updates to the CoE LT and DPLT.
Desired Qualifications
  • A Master’s degree (MBA or equivalent) is highly preferred.
  • Professional certifications such as Chartered Institute of Procurement and Supply (CIPS) are highly preferred.
  • German language skills are a strong asset.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Roche targets top-three obesity status by 2030 via CT-388 and petrelintide assets.
  • The $1.5B Poseida acquisition secures off-the-shelf CAR-T therapies for oncology and immunology.
  • AI-driven diagnostics gain traction through the $750M PathAI acquisition closing in 2026 H2.

What critics are saying

  • Kadcyla and Perjeta biosimilar erosion in 2025–2026 will strip billions from oncology revenue.
  • Ocrevus loss of exclusivity in 2029 threatens the entire immunology franchise profitability.
  • Eight cancer drugs face biosimilars by 2030, risking CHF 6.7B sales decline easily.

What makes Roche unique

  • Roche uniquely integrates Pharmaceuticals and Diagnostics under one roof for personalized healthcare.
  • Only Roche combines world-class drug R&D with global diagnostics leadership seamlessly.
  • Roche leverages companion diagnostics to pair targeted therapies with precise patient identification.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.